MACULAR ATROPHY INCIDENCE IN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR-TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Risk Factor Evaluation for Individualized Treatment Need of Ranibizumab or Aflibercept According to an Observe-and-Plan Regimen.

Metadatas

Authors
Discipline
type
Scope
Language
Identifiers
Source

Serveur académique Lausannois

Relations

This document is linked to :
info:eu-repo/semantics/altIdentifier/doi/10.1097/IAE.0000000000002054

This document is linked to :
info:eu-repo/semantics/altIdentifier/pmid/29370035

This document is linked to :
info:eu-repo/semantics/altIdentifier/eissn/1539-2864

This document is linked to :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_160E4E5271F03

Collection

Serveur Académique Lausannois

Organization

Université de Lausanne et CHUV

Licenses

info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/

Keywords 0

Aged; Angiogenesis Inhibitors/administration & dosage; Angiogenesis Inhibitors/adverse effects; Atrophy/chemically induced; Atrophy/diagnosis; Atrophy/epidemiology; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorescein Angiography; Fundus Oculi; Humans; Incidence; Intravitreal Injections; Macula Lutea/drug effects; Macula Lutea/pathology; Male; Prognosis; Prospective Studies; Ranibizumab/administration & dosage; Ranibizumab/adverse effects; Receptors, Vascular Endothelial Growth Factor/administration & dosage; Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors; Recombinant Fusion Proteins/administration & dosage; Recombinant Fusion Proteins/adverse effects; Risk Factors; Switzerland/epidemiology; Tomography, Optical Coherence; Visual Acuity; Wet Macular Degeneration/diagnosis; Wet Macular Degeneration/drug therapy

Similar subjects En

Therapy Jabs (Injections) Shots (Injections)

Cite this document

I. Mantel et al., « MACULAR ATROPHY INCIDENCE IN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR-TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Risk Factor Evaluation for Individualized Treatment Need of Ranibizumab or Aflibercept According to an Observe-and-Plan Regimen. », Serveur académique Lausannois, ID : 10.1097/IAE.0000000000002054

Metrics

Share / Export

Abstract 0

To investigate factors associated with macular atrophy (MA) incidence in neovascular age-related macular degeneration treated with either ranibizumab or aflibercept in an Observe-and-Plan variable dosing regimen. Information was obtained from two identical prospective treatment protocols using ranibizumab or aflibercept in a variable dosing regimen termed "Observe and Plan." Eyes without MA at baseline were included. New atrophy at the final 2-year visit was investigated with univariate and multivariate analysis to identify associated risk factors, focusing on treatment factors. De novo MA developed in 63 (42%) of 149 eyes/patients (mean age 79.0 years), in 70 eyes treated using aflibercept and 79 eyes using ranibizumab. The univariate analysis showed multiple associations of MA with baseline factors, of which the following were confirmed as independent risk factors after multivariate stepwise logistic regression: lower number of anti-vascular endothelial growth factors injections (P = 0.011), depigmentation (P = 0.0004), reticular pseudodrusen (P = 0.0005), lower baseline visual acuity (P = 0.0006), and retinal angiomatous proliferation (P = 0.001). The drug type showed no significant association with MA incidence (P = 0.21). Within the variable dosing regimen, MA incidence was higher when fewer injections were required. More injections, if required by disease activity, did not increase the risk for MA.

document thumbnail

From the same authors

On the same subjects

Within the same disciplines